Biovia supports ALCOVE: early lung cancer detection through breath analysis
With the support of Biovia as associate partner, ALCOVE aims to improve lung cancer screening through an innovative, accessible and non-invasive tool, tailored to the needs of healthcare providers, researchers and patients.
Lung cancer is currently one of the leading causes of cancer-related deaths in Europe. As the disease is often diagnosed at a late stage, it results in a poor overall prognosis, with only a 17% chance of surviving five years past diagnosis. However, with early detection, the five-year survival rate can increase to 90% thanks to curative surgical treatment.
ALCOVE is a cross-border, EU co-funded research initiative (Interreg France – Wallonia – Flanders) aiming to revolutionize lung cancer screening by developing and clinically validating a non-invasive ‘electronic nose’ that detects volatile organic compounds in exhaled breath associated with an increased risk of lung cancer.
Seventeen partners, including nine hospitals in Belgium and France, will test the device on patients at risk or diagnosed with lung cancer. The ultimate goal is to introduce the detection device in general practitioner offices, pharmacies and healthcare facilities, thereby facilitating more accessible and simplified screening and improving patients’ chances of survival.
Want to learn more about ALCOVE? Check out the project website (Dutch and French): https://alcove.crosss3.eu/nl/